Role of TFEB in Huntington's Disease

Area of Science:

• Neurodegenerative diseases
• Molecular biology
• Genetics

Background:

• Huntington's disease (HD) is a neurodegenerative disorder caused by CAG repeat expansion in the huntingtin (HTT) gene.
• This expansion results in mutant huntingtin protein (mHTT) aggregation, impairing neuronal function through various cellular dysfunctions.
• Autophagy and lysosomal pathways are crucial for clearing mHTT, and their dysfunction contributes significantly to HD pathogenesis.

Purpose of the Study:

• To investigate the role of Transcription Factor EB (TFEB) in modulating autophagy for potential Huntington's disease therapy.
• To explore whether enhancing TFEB activity can promote the clearance of mutant huntingtin aggregates and ameliorate disease phenotypes.

Main Methods:

• Review of existing evidence on TFEB's function as a master regulator of autophagy and lysosomal biogenesis.
• Analysis of studies investigating TFEB modulation in the context of Huntington's disease models.
• Examination of conflicting findings regarding TFEB overexpression and its impact on mHTT aggregation and disease progression.

Main Results:

• TFEB controls key genes involved in autophagosome formation, lysosomal function, and autophagic flux.
• Some studies suggest TFEB activation aids mHTT aggregate clearance and improves HD phenotypes.
• Conversely, other research indicates TFEB overexpression might exacerbate HD by promoting mHTT co-aggregation.

Conclusions:

• Modulating TFEB activity presents a potential therapeutic strategy for Huntington's disease by enhancing intracellular clearance mechanisms.
• Conflicting results highlight the need for further investigation into TFEB's precise role and safety in different HD models.
• Confirming TFEB's efficacy and safety is crucial before considering it as a viable therapeutic approach for mHTT-mediated toxicity.